Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
Last week, Breast Cancer Now was invited to give evidence to the Health and Social Care Select Committee’s inquiry on cancer services.
In October 2021, we were very disappointed to learn that the National Institute for Health and Care Excellence (NICE) was provisionally unable to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS.
Baroness Delyth Morgan, CEO of Breast Cancer Now, tells us about some of the things she's been part of in her 25 years with the charity, as well as how we are focusing more on people with secondary breast cancer.
We’re committed to improving treatment, care and services for people living with secondary breast cancer, which is why it’s a central part of our new strategy.
Today, we are excited to announce that we have finally secured a long-overdue secondary breast cancer audit in England, delivering on one of the key calls from our Unsurvivors campaign.
In 2017, Jen received a de novo diagnosis of secondary breast cancer after experiencing some unusual symptoms. She tells us about the misconceptions she had about cancer, and how she's working with Breast Cancer Now to campaign for change.
The experiences of people living with secondary breast cancer are unique, which is why our secondary breast cancer campaign has been calling for these experiences to be acknowledged and understood.
A new targeted drug for treating breast cancer that has spread has been approved by the National Institute for Health and Care Excellence (NICE) for use on the Cancer Drugs Fund.
Our 2019 report, which looked at the experiences of over 2,000 people living with secondary breast cancer, found that many were experiencing avoidable delays in diagnosis.